Since the publication (9), some 12 years ago, of a standardized procedure for the study of blood coagulation reactions (in vitro), which has been the basis of a large number of investigations in the senior author's laboratories during the intervening years, there have been significant advances toward the purification of many of the clotting factors. In particular, these advances now permit us to qualify the statement of our 1938 paper that (as compared with the rate of the thrombin-fibrinogen reaction)... "the consideration of amount of fibrin f o r m e d . . , is governed by a different set of factors, notable among which are questions related to quantity of thrombin and weight of the clot (Eagle (7)), neither of which can as yet be dignified with a biochemical signific a n c e . . . " Thrombin (30) and prothrombin 432) of great potency and reasonably satisfactory purity (12) are now available from bovine plasma. Thrombins of other species, e.g. rabbit (29), human (5), in our experience, have proved somewhat less reliable (see below) for research studies. The Human Plasma Fractionation program, developed at Harvard under the direction of Dr. E. J. Cohn (4) and colleagues (8), has yielded successful fibrinogen (and fibrin) preparations and these technics have been adapted to bovine plasma, especially in the instance of "fibrinogen" (fraction I) now commercially available from the Armour Laboratories (24). J. D. Ferry and Morrison (13) and Morrison (27) utilized the Harvard human plasma fractions to obtain a considerable body of data concerning the thrombin-fibrinogen reaction and many aspects of fibrin formation and fibrin yields. Our independent studies on materials of bovine and other species have been carried on for a number of years and the data accumulated for the present publication should be reviewed in the light of the Harvard investigations. It will be noted that we have carried certain confirmatory experiments somewhat further into technical details and have added new data on the topics of "fibrinoplastic" factors, the (alleged) "profibrin" question, and problems relating to thrombin stability.